Skip to main content

Tonix Pharmaceuticals announces acquisition of Healion Bio antiviral portfolio

Tonix Pharmaceuticals CEO Seth Lederman joins Proactive's Natalie Stoberman to announce the acquisition of Healion Bio, including its entire portfolio of next-generation antiviral technology assets.

Lederman said the acquired portfolio of infectious disease assets includes a class of potential broad-spectrum antiviral agents, TNX-3900, with a host-directed mechanism. Tonix said it plans to develop the TNX-3900 series of molecules as oral antivirals, either as monotherapy or in combination with other antivirals.

Contact Details

Proactive USA

+1 347-449-0879

na-editorial@proactiveinvestors.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.